Showing results (301-310 of 432) with videos related to

Sort By:
Pageof 44
Autoimmunity Reviews|December 16, 2019
Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature reviewAnne Laure Roupie, Hubert de Boysson, Sara Thietart, et al.
Leukemia|February 21, 2020
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative StudySabine Kayser, Ramy Rahmé, David Martínez-Cuadrón, et al.
JAMA Dermatology|November 19, 2025
Lupuslike Manifestations in Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaJeanne Chauffier, Vincent Jachiet, Maxime Battistella, et al.
The Lancet. Haematology|May 28, 2023
CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 studyPierre Peterlin, Yannick Le Bris, Pascal Turlure, et al.
Blood|August 12, 2009
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)Olivier Kosmider, Véronique Gelsi-Boyer, Meyling Cheok, et al.
Haematologica|May 28, 2016
A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agentsSylvain Thépot, Raouf Ben Abdelali, Sylvie Chevret, et al.
Lancet (London, England)|December 4, 2023
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trialUwe Platzbecker, Valeria Santini, Pierre Fenaux, et al.
Blood|August 15, 2013
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cellsStephanie Beurlet, Nader Omidvar, Petra Gorombei, et al.
Blood|November 30, 2016
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelHartmut Döhner, Elihu Estey, David Grimwade, et al.
Hemasphere|June 17, 2026
Mutational dynamics in patients with del(5q) MDS treated with lenalidomide prior to transfusion dependency-Molecular results from the Sintrarev clinical trialSofía Toribio Castelló, Felix López-Cadenas, Claude Preudhomme, et al.
Pageof 44